Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECBK | VERU |
|---|---|---|
| Founded | 1919 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.1M | 41.7M |
| IPO Year | 2022 | 1996 |
| Metric | ECBK | VERU |
|---|---|---|
| Price | $17.08 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 6.0K | ★ 52.2K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.55 | $0.36 |
| 52 Week High | $20.05 | $4.59 |
| Indicator | ECBK | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 42.29 |
| Support Level | $15.16 | $2.15 |
| Resistance Level | $17.38 | $2.70 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 29.14 | 0.00 |
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.